These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 21883998)

  • 21. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
    Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV
    Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
    Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Azmoon S; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New directions in antiplatelet therapy.
    Ferreiro JL; Angiolillo DJ
    Circ Cardiovasc Interv; 2012 Jun; 5(3):433-45. PubMed ID: 22715450
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.
    Paniccia R; Antonucci E; Maggini N; Miranda M; Gori AM; Marcucci R; Giusti B; Balzi D; Prisco D; Abbate R
    Thromb Haemost; 2010 Aug; 104(2):287-92. PubMed ID: 20458439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical use of clopidogrel.
    Sarafoff N; Byrne RA; Sibbing D
    Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
    Máchal J; Hlinomaz O
    Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey.
    Gurbel PA; Tantry US
    Thromb Haemost; 2011 Aug; 106(2):265-71. PubMed ID: 21713326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
    Bernlochner I; Byrne RA; Kastrati A; Sibbing D
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
    Oprea AD; Popescu WM
    J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080
    [No Abstract]   [Full Text] [Related]  

  • 34. Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice.
    Sibbing D; Orban M; Massberg S
    Hamostaseologie; 2013; 33(1):9-15. PubMed ID: 23299202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
    Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
    J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and clinical use of prasugrel and ticagrelor.
    Ahmad S; Storey RF
    Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.
    Ferreiro JL; Ueno M; Tello-Montoliu A; Tomasello SD; Seecheran N; Desai B; Rollini F; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2013 Feb; 6(2):182-4. PubMed ID: 23428011
    [No Abstract]   [Full Text] [Related]  

  • 38. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists.
    Tang J; Li MP; Zhou HH; Chen XP
    Curr Vasc Pharmacol; 2015; 13(5):566-77. PubMed ID: 25440595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of perioperative antiplatelet therapy and platelet reactivity testing in carotid revascularization: overview of the evidence.
    Leunissen TC; De Borst GJ; Janssen PW; ten Berg JM
    J Cardiovasc Surg (Torino); 2015 Apr; 56(2):165-75. PubMed ID: 25600432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.